Kip Wolf is a life sciences executive and applied researcher whose work sits at the intersection of information science, data integrity, and AI governance in regulated environments. He helps biopharma leaders improve patient outcomes, safeguard public health, and support national security priorities by serving as an executive advisor.

A Navy veteran, serial entrepreneur, and doctoral researcher in Information Science (Drexel University, beginning fall 2026), Kip brings more than thirty years of biopharma operations experience to the question most regulated companies get wrong: not whether their data is accurate, but whether their information systems are built to keep it that way.

His original research in data integrity and AI governance gives clients something most fractional operators and consulting firms cannot offer: thirty years of applied insight into where information systems break down, and a practitioner-built methodology grounded in data provenance, metadata governance, and risk-based data lifecycle design that builds regulatory defensibility and exit value into operations from day one.

Published Authority

Kip co-led and co-authored ASQ TR3:2022, the American Society for Quality's industry-agnostic data integrity standard. Since 2017, he has served as sub-team co-leader of the AI in Operations working group under the Pathway for Patient Health Collaborative Community (previously under Healthcare Products Collaborative and Xavier Health), advancing predictive assurance of product quality across life sciences manufacturing, quality, and supply chain through AI and machine learning.

He has published more than twenty professionally peer-reviewed articles and book chapters, and has keynoted conferences including the Waters Informatics Users' Conference, ISPE Annual Meeting, and the Honeywell Life Sciences Customer Advisory Board.

Operational Track Record

At X-Vax Technology, Kip served as VP of Technical Operations and Portfolio Management for a pre-clinical biotech startup. He built and led the PMO from the ground up, overseeing a portfolio of live virus vaccine and monoclonal antibody R&D programs across 50+ external partners in 6 time zones and 7 countries. His forecasting, operational strategy, and due diligence readiness work were instrumental in enabling a $56M upsized Series A.

Selected results include:
▸ $24.8M program benefit: led a $12.4M portfolio of strategic regulatory projects.
▸ $120M+ PMO: directed 100+ integration initiatives for global regulatory organization post merger.

Earlier, as founder and CEO of GxP Data Services (1997), he built an established leader in systems management, regulatory compliance, and computer system validation serving clients from start-ups to Fortune 500 companies, including Pfizer, Roche Diagnostics, Wyeth Pharmaceuticals, Isis Pharmaceuticals, Lockheed Martin, and Newport News Shipbuilding.